Improvac
Gonadotropin releasing factor (GnRF) analogue-protein conjugate
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Improvac.It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Improvac.
For practical information about using Improvac, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
Improvac
|
Agency product number |
EMEA/V/C/000136
|
Active substance |
Synthetic peptide analogue of GnRF conjugated to diptheria toxoid
|
International non-proprietary name (INN) or common name |
Gonadotropin releasing factor (GnRF) analogue-protein conjugate
|
Species |
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI09AX
|
Publication details | |
---|---|
Marketing-authorisation holder |
Zoetis Belgium SA
|
Revision |
20
|
Date of issue of marketing authorisation valid throughout the European Union |
11/05/2009
|
Contact address |
Rue Laid Burniat 1 |
Product information
20/01/2022 Improvac - EMEA/V/C/000136 - II/0036
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunologicals for suidae
Therapeutic indication
Male pigs:
Induction of antibodies against GnRF to produce a temporary immunological suppression of testicular function. For use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. Another key contributor to boar taint, skatole, may also be reduced as an indirect effect. Aggressive and sexual (mounting) behaviours are also reduced.
Female pigs:
Induction of antibodies against GnRF to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).